Expectations for artificial intelligence’s use in pharma research typically skew heavily on ingredients which would be Rx-only, but firms looking at making additional drugs available OTC could have as much or more to gain.
Jo Varshney, founder and CEO of AI startup VeriSIM Life Inc., recently told HBW Insight that firms moving ingredients from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?